Abstract
Purpose
Receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin (RANKL/RANK/OPG) axis has been hypothesized as a potential mediator of left ventricular hypertrophy (LVH). The aim of the study was to assess whether circulating concentrations of RANKL, RANK, and OPG were associated with early signs of morphological cardiac changes in overweight/obese youths.
Methods
We determined serum levels of RANKL, RANK and OPG by enzyme-linked immunosorbent assays in 188 overweight/obese children and adolescents. LV mass index (LVMI) and relative wall thickness (RWT) were estimated using M-mode echocardiography.
Results
OPG and RANKL levels were higher among girls than among boys [1.73 (1.64–1.86) and 3.28 (1.90–6.37) pmol/L, respectively, vs. 1.69 (1.59–1.82) and 2.12 (1.52–3.80) pmol/L; p = 0.02 and p = 0.0001, respectively], but the OPG/RANKL ratio was lower [0.52 (0.26–0.88) vs 0.77 (0.44–1.11); p = 0.001]. In gender-specific multivariate linear regression, OPG/RANKL ratio was associated with LVMI and RWT in boys but not in girls. In multiple logistic regression, after adjustment for clinical variables, OPG/RANKL ratio was associated with concentric remodeling, eccentric and concentric LVH in boys but not in girls.
Conclusion
OPG/RANKL ratio is independently associated with LVH and patterns of LV structural remodeling in male overweight/obese children and adolescents.
Similar content being viewed by others
References
Brady TM (2016) The role of obesity in the development of left ventricular hypertrophy among children and adolescents. Curr Hypertens Rep 18:3
Lavie CJ, Patel DA, Milani RV, Ventura HO, Shah S, Gilliland Y (2014) Impact of echocardiographic left ventricular geometry on clinical prognosis. Prog Cardiovasc Dis 57:3–9
Lai CC, Sun D, Cen R, Wang J, Li S, Fernandez-Alonso C, Chen W, Srinivasan SR, Berenson GS (2014) Impact of long-term burden of excessive adiposity and elevated blood pressure from childhood on adulthood left ventricular remodeling patterns: the Bogalusa heart study. J Am Coll Cardiol 64:1580–1587
Yang H, Huynh QL, Venn AJ, Dwyer T, Marwick TH (2017) Associations of childhood and adult obesity with left ventricular structure and function. Int J Obes 41:560–568
Yan Y, Liu J, Wang L, Hou D, Zhao X, Cheng H, Mi J (2017) Independent influences of excessive body weight and elevated blood pressure from childhood on left ventricular geometric remodeling in adulthood. Int J Cardiol 243:492–496
Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, de Lemos JA (2007) Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 49:1392–1398
Noheria A, Mosley TH Jr, Kullo IJ (2010) Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension. Am J Hypertens 23:767–774
Lu J, Liu F, Liu D, Du H, Hao J, Yang X, Cui W (2016) Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats. Exp Biol Med (Maywood) 241:1237–1249
Hao Y, Tsuruda T, Sekita-Hatakeyama Y, Kurogi S, Kubo K, Sakamoto S, Hatakeyama K, Chosa E, Asada Y, Kitamura K (2016) Cardiac hypertrophy is exacerbated in aged mice lacking the osteoprotegerin gene. Cardiovasc Res 110:62–72
Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, Niforas P, Ng KW, Martin TJ, Gillespie MT (1999) Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extra skeletal tissues. Bone 25:525–534
Baud’huin M, Lamoureux F, Duplomb L, Rédini F, Heymann D (2007) RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci 64:2334–2350
Montagnana M, Lippi G, Danese E, Guidi GC (2013) The role of osteoprotegerin in cardiovascular disease. Ann Med 45:254–264
Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K (2008) Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 51:627–633
Suliburska J, Bogdanski P, Gajewska E, Kalmus G, Sobieska M, Samborski W (2013) The association of insulin resistance with serum osteoprotegerin in obese adolescents. J Physiol Biochem 69:847–853
Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njølstad I, Jørgensen L, Hansen JB (2010) Relation between serum osteoprotegerin and carotid intima media thickness in a general population—the Tromsø Study. J Thromb Haemost 8:2133–2139
Pepene CE, Ilie IR, Marian I, Duncea I (2011) Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. Eur J Endocrinol 164:61–68
Tschiderer L, Willeit J, Schett G, Kiechl S, Willeit P (2017) Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. PLoS ONE 12:e0183910
Pacifico L, Cantisani V, Ricci P, Osborn JF, Schiavo E, Anania C, Chiesa C (2008) Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res 63:423–427
Cole TJ, Bellizzi MC, Flegal KM, Dietz WH (2000) Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 320:1240–1243
Pacifico L, Di Martino M, De Merulis A, Bezzi M, Osborn JF, Catalano C, Chiesa C (2014) Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 59:461–470
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al (2006) Recommendations for chamber quantification. Eur J Echocardiogr 7:79–108
Khoury PR, Mitsnefes M, Daniels SR, Kimball TR (2009) Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr 22:709–714
Di Bonito P, Moio N, Sibilio G, Cavuto L, Sanguigno E, Forziato C, de Simone G, Capaldo B (2014) Cardiometabolic phenotype in children with obesity. J Pediatr 165:1184–1189
Song DH, Zhou PZ, Xiu XL, Zhou GH, Sun YX, Song C (2016) Relationships of OPG genetic polymorphisms with susceptibility to cardiovascular disease: a meta-analysis. Med Sci Monit 22:1223–1231
Kiechl S, Schett G, Schwaiger J, Seppi K, Eder P, Egger G, Santer P, Mayr A, Xu Q, Willeit J (2007) Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation 116:385–391
Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJ, Khaw KT, Boekholdt SM (2009) Osteoprotegerin and soluble receptor activator of nuclear factor-kappa B ligand and risk for coronary events: a nested case–control approach in the prospective EPIC-Norfolk population study 1993–2003. Arterioscler Thromb Vasc Biol 29:975–980
Schoppet M, Schaefer JR, Hofbauer LC (2003) Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation 107:e76
Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF Jr, Rong J, Corey D, Hoffmann U, Fox CS, Vasan RS, Benjamin EJ, O’Donnell CJ, Kathiresan S (2010) Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 30:1849–1854
Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Müller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damås JK, Frøland SS, Hansson GK, Halvorsen B, Aukrust P (2006) Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 226:857–863
Ueland T, Yndestad A, Dahl CP, Gullestad L, Aukrust P (2012) TNF revisited: osteoprotegerin and TNF-related molecules in heart failure. Curr Heart Fail Rep 9:92–100
Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E (2007) The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 156:555–562
Litwin SE (2014) Childhood obesity and adult cardiovascular disease. J AM Coll Cardiol 64:1588–1590
Caprio S, Perry R, Kursawe R (2017) Adolescent obesity and insulin resistance: roles of ectopic fat accumulation and adipose inflammation. Gastroenterology 152:1638–1646
Skinner AC, Perrin EM, Moss LA, Skelton JA (2015) Cardiometabolic risks and severity of obesity in children and young adults. N Engl J Med 373:1307–1317
Srinivasan SR, Bao W, Wattigney WA, Berenson GS (1996) Adolescent overweight is associated with adult overweight and related multiple cardiovascular risk factors: the Bogalusa Heart Study. Metabolism 45:235–240
Freedman DS, Mei Z, Dietz WH, Srinivasan SR, Berenson GS (2001) Relationship of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart Study. Pediatrics 108:712–718
Urbina EM, Gidding SS, Bao W, Pickoff AS, Berdusis K, Berenson GS (1995) Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study. Circulation 91:2400–2406
Li X, Li S, Ulusoy E, Chen W, Srinivasan SR, Berenson GS (2004) Childhood adiposity as a predictor of cardiac mass in adulthood: the Bogalusa Heart Study. Circulation 110:3488–3492
Toprak A, Wang H, Chen W, Paul T, Srinivasan S, Berenson G (2008) Relation of childhood risk factors to left ventricular hypertrophy (eccentric or concentric) in relatively young adulthood (from the Bogalusa Heart Study). Am J Cardiol 101:1621–1625
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No disclosure for any prior publication or submission. No conflict of interest or role of any sponsor is present in this work. The authors alone are responsible for the content and the writing of the paper.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individuals, parents/guardians of participants included in the study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zampetti, S., Lucantoni, F., Pacifico, L. et al. Association of OPG–RANKL ratio with left ventricular hypertrophy and geometric remodeling in male overweight/obese youths. J Endocrinol Invest 42, 427–434 (2019). https://doi.org/10.1007/s40618-018-0932-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-018-0932-y